AGK在血栓形成中的作用及潜在治疗策略
本研究探讨AGK在巨核细胞发育和血小板生成中的作用。巨核细胞/血小板特异性AGK缺陷小鼠出现血小板减少和脾肿大,主要源于骨髓血小板生成障碍和髓外造血过度,而非循环血小板凋亡。AGK与JAK2结合,JAK2 V617F突变增强该结合并促进JAK2/Stat3信号;含YGVCF617CGDENI序列的细胞穿透肽可加速前血小板形成。
要点
- AGK缺陷导致血小板减少和脾肿大,机制为骨髓血小板生成障碍和髓外造血过度。
- AGK G126E突变不影响外周血小板计数或巨核细胞分化,提示其作用不依赖激酶活性。
- 靶向AGK与JAK2相互作用可能是治疗血小板减少或血小板增多症的新策略。
核心结论
- AGK在巨核细胞分化和血小板生成中起关键作用,且不依赖其激酶活性。
- AGK与JAK2结合,JAK2 V617F突变增强结合并促进JAK2/Stat3信号。
- 靶向AGK-JAK2相互作用可能治疗血小板减少或血小板增多症。
研究设计与样本
- 使用巨核细胞/血小板特异性AGK缺陷小鼠模型。
- 研究AGK G126E突变对血小板计数和巨核细胞分化的影响。
- 分析AGK与JAK2的结合及JAK2 V617F突变的作用。
- 测试含YGVCF617CGDENI序列的细胞穿透肽对前血小板形成的影响。
主要发现
- AGK缺陷小鼠出现血小板减少和脾肿大,由骨髓血小板生成障碍和髓外造血过度导致。
- AGK G126E突变不影响外周血小板计数或巨核细胞分化。
- AGK可与巨核细胞/血小板中的JAK2结合。
- JAK2 V617F突变显著增强AGK与JAK2结合并促进JAK2/Stat3信号。
- 含YGVCF617CGDENI序列的细胞穿透肽加速前血小板形成。
关键数值与推荐
- AGK缺陷小鼠出现血小板减少和脾肿大。
- AGK G126E突变不影响外周血小板计数或巨核细胞分化。
- JAK2 V617F突变增强AGK与JAK2结合并促进JAK2/Stat3信号。
- 含YGVCF617CGDENI序列的细胞穿透肽加速前血小板形成。
临床怎么用
- AGK可能作为血小板减少或血小板增多症的潜在治疗靶点。
- 靶向AGK与JAK2相互作用或为新型治疗策略。
- 含YGVCF617CGDENI序列的肽类分子或可促进血小板生成。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Abnormal megakaryocyte development and platelet production lead to thrombocytopenia or thrombocythemia and increase the risk of hemorrhage or thrombosis. Acylglycerol kinase (AGK) is a mitochondrial membrane kinase that catalyzes the formation of phosphatidic acid and lysophosphatidic acid. Mutation of AGK has been described as the major cause of Sengers syndrome, and the patients with Sengers syndrome have been reported to exhibit thrombocytopenia. In this study, we found that megakaryocyte/platelet-specific AGK-deficient mice developed thrombocytopenia and splenomegaly, mainly caused by inefficient bone marrow thrombocytopoiesis and excessive extramedullary hematopoiesis, but not by apoptosis of circulating platelets. It has been reported that the G126E mutation arrests the kinase activity of AGK. The AGK G126E mutation did not affect peripheral platelet counts or megakaryocyte differentiation, suggesting that the involvement of AGK in megakaryocyte development and platelet biogenesis was not dependent on its kinase activity. The Mpl/Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (Stat3) pathway is the major signaling pathway regulating megakaryocyte development. Our study confirmed that AGK can bind to JAK2 in megakaryocytes/platelets. More interestingly, we found that the JAK2 V617F mutation dramatically enhanced the binding of AGK to JAK2 and greatly facilitated JAK2/Stat3 signaling in megakaryocytes/platelets in response to thrombopoietin. We also found that the JAK2 JAK homology 2 domain peptide YGVCF617CGDENI enhanced the binding of AGK to JAK2 and that cell-permeable peptides containing YGVCF617CGDENI sequences accelerated proplatelet formation. Therefore, our study reveals critical roles of AGK in megakaryocyte differentiation and platelet biogenesis and suggests that targeting the interaction between AGK and JAK2 may be a novel strategy for the treatment of thrombocytopenia or thrombocythemia.
引用
- Jiang H, Yu Z, Ding N, et al. The role of AGK in thrombocytopoiesis and possible therapeutic strategies. Blood. 2020. PMID: 32202634. doi:10.1182/blood.2019003851
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。